ClinicalTrials.gg

Program

PRMT5 Inhibitor IDE892

Its studies are mostly in Adenocarcinoma Of Esophagus, led by IDEAYA Biosciences.

Furthest: phase 1, since Nov 13, 20251 company-led study, 1 open or runningNext primary completion: Apr 30, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
IDEAYA Biosciences11 open or runningphase 1since Nov 13, 2025Nov 13, 2025Apr 30, 2028phase 1 · NCT07277413

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 13, 2025First study: phase 1 study in Adenocarcinoma Of EsophagusFirst studyNCT07277413 · 260 planned · United States, South Korea

Ahead

  1. Apr 30, 2028Primary completion: phase 1 study in Adenocarcinoma Of EsophagusNCT07277413

TargetBeta

PRMT5 →read by rule
“An orally bioavailable methylthioadenosine (MTA)-selective inhibitor of the protein arginine methyltransferase 5 (PRMT5), ”NCIt, by rule

Other programs on PRMT5

ProgramCompanyFurthest phaseStudies
navlimetostatBristol-Myers Squibbphase 310
PRMT5 Inhibitor AZD3470AstraZenecaphase 22
JBI-778rulejubilant-therapeutics-india-limitedphase 22
PRMT5 Inhibitor TNG456ruletango-therapeutics-incphase 21
PRMT5 Inhibitor BAY 3713372ruleBayerphase 21
onametostatruleJohnson & Johnsonphase 12
PRMT5 Inhibitor SH3765ruleNanjing Sanhome Pharmaceuticalphase 12
PRMT5 Inhibitor BGB-58067ruleBeOne Medicinesphase 12
PEP08rulepharmaenginephase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07277413Adenocarcinoma Of Esophagus · United States, South Korea1RecruitingApr 30, 2028260

How it is read

Names in the registry

  • “IDE892”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.